Fiscal Period | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
Issuance( Retirement)of Debt Net | -18.73 | -18.13 | -16.87 | -15.62 |
Net Changein Cash | 474.68 | 29.23 | -251.25 | -119.00 |
Cash Taxes Paid | 81.71 | 254.23 | 264.71 | 120.51 |
Net Income/ Starting Line | 1,255.19 | 959.80 | 837.37 | 767.47 |
Total Cash Dividends Paid | -749.38 | -541.57 | -1,525.50 | -506.64 |
Changesin Working Capital | 103.12 | -193.20 | -310.45 | -0.64 |
Cashfrom Operating Activities | 1,289.90 | 582.02 | 484.23 | 810.75 |
Cash Interest Paid | 1.31 | 1.80 | 1.40 | 1.99 |
Cashfrom Financing Activities | -769.42 | -561.50 | -1,543.32 | -524.24 |
Depreciation/ Depletion | 66.79 | 69.68 | 65.77 | 68.19 |
Other Investing Cash Flow Items Total | -21.08 | 39.93 | 851.89 | -370.87 |
Capital Expenditures | -24.72 | -31.22 | -44.04 | -34.64 |
period Type | - | - | - | - |
Non- Cash Items | -135.20 | -254.26 | -108.46 | -24.27 |
Financing Cash Flow Items | -1.31 | -1.80 | -0.96 | -1.99 |
period Length | 12.00 | 12.00 | 12.00 | 12.00 |
Cashfrom Investing Activities | -45.80 | 8.71 | 807.85 | -405.51 |
Glaxosmithkline Pharmaceutical Dividend Glaxosmithkline Pharmaceutical Bonus Glaxosmithkline Pharmaceutical News Glaxosmithkline Pharmaceutical AGM Glaxosmithkline Pharmaceutical Rights Glaxosmithkline Pharmaceutical Splits Glaxosmithkline Pharmaceutical Board Meetings Glaxosmithkline Pharmaceutical Key Metrics Glaxosmithkline Pharmaceutical Shareholdings Glaxosmithkline Pharmaceutical Profit Loss Glaxosmithkline Pharmaceutical Balance Sheet Glaxosmithkline Pharmaceutical Q1 Results Glaxosmithkline Pharmaceutical Q2 Results Glaxosmithkline Pharmaceutical Q3 Results Glaxosmithkline Pharmaceutical Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks